Description
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor platform. The Company has developed a platform that enables to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer T-cell receptors (TCRs), and produce TCR therapeutic candidates for administration to patients. The Company's target peptides are NY-ESO-1 and MAGE A-10. The Company's affinity-enhanced TCR therapeutics targets the NY-ESO-1, or NY-ESO, cancer antigen. The Company has completed the Phase I/II clinical trials for its NY-ESO TCR therapeutic candidate, in patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer and esophageal cancer.
Address
91 Park Drive
ABINGDON, OX14 4RY
United Kingdom
ABINGDON, OX14 4RY
United Kingdom
Key stats and ratios
| Q4 (Dec '14) | 2014 | |
| Net profit margin | -127.81% | -2100.84% |
| Operating margin | -211.14% | -2376.90% |
| EBITD margin | - | -2335.49% |
| Return on average assets | - | -44.15% |
| Return on average equity | - | - |
| Employees | 78 |
